Morning Wealth



Friday 2nd August, 2019

Nifty Futures	Level 1	Level 2	Level 3
Resistance	11030	11080	11140
Support	10920	11880	10830
Indices (NSE)	Close	Pts. Chg	% Chg
Nifty	10980.0	-138.0) -1.2
Nifty Future (Aug)	11032.0	-100.2	2 -0.9
Nifty Future (Sep)	11086.3	-98.7	7 -0.8
Bank Nifty	28367.3	-508.8	3 -1.8
Nifty 100	11080.9	-140.3	3 -1.3
Nifty 500	8935.8	-109.2	2 -1.2
Nifty Midcap	15754.5	-166.7	7 -1.0

Indices (BSE)	Close	Pts. Chg	% Chg
Sensex	37018.3	-462.8	-1.2
BSE-100	11077.3	-133.5	-1.2
BSE-200	4578.9	-55.8	-1.2
BSE-500	4021.7	-48.7	-1.2
Mid Cap	13526.5	-116.9	-0.9
Small Cap	12551.9	-140.2	-1.1

Sectoral Indices	Close	Pts. Chg	% Chg
BANKEX	32101.0	-588.4	-1.8
CAPITAL GOODS	17249.2	-306.8	-1.8
REALTY	2046.3	-20.8	-1.0
POWER	1963.9	-2.4	-0.1
OIL & GAS	13174.8	-62.1	-0.5
METAL	9359.4	-326.0	-3.4
CD	22390.2	47.9	0.2
AUTO	15469.8	-2.2	0.0
TECK	7527.8	-159.1	-2.1
IT	15431.4	-302.1	-1.9
FMCG	11012.8	-49.6	-0.5
HEALTHCARE	12587.2	-117.2	-0.9
VIX	14.6	1.0	7.1

Exchange	Advance	Decline	Unchg
BSE	778	1689	121
NSE	530	1289	94

Volume	Rs (in cr)	% Chg
NSE Cash	33533.0	-8.9
BSE Cash	2093.3	-21.5
NSE F&O	2799622.8	83.5

Net Inflows/ Outflows (Rs in cr)	Buy	Sell	Net
FII	5161.3	6217.8	-1056.6
DII	4591.2	4029.9	561.3

Intraday Nifty Outlook

Nifty spot closed 1.24% lower at 10980. Index opened gap down and continued its lower high lower low formations for fourth consecutive day. Going ahead index has immediate resistance at 11030, for index to see any meaningful relief it needs to surpass this level which if it does will call for relief towards 11080-11140 while support comes at 10920-10880.

Corporate News

Voltas eyes ₹50-cr business from Kerala this Onam

Kerala has emerged as the fastest growing market for Voltas Ltd in the air-conditioner segment, registering a 163 per cent growth in Q1 of FY20.According to Pradeep Bakshi, Managing Director and CEO, the company sold 35,000 units in the first quarter and he attributes the growth to factors such as harsh summer, pent up demand and easy consumer finance options. Expressing concerns over the possible slowdown in the economy, he said the performance in the first quarter shows that the company may overcome the situation. "If the summer is harsh, no matter our product category may go up," Bakshi, who was in Kochi to kick start the company's Onam festival offers, said. Nationally, the first quarter sales was good, enabling the company to garner a 50 per cent market share. "We have been closing the one-million mark in the last three years. However, the season this year was supportive as we have crossed 1 million in the first five months and looking at 1.5 million mark by the year end", he added. (Source: Businessline)

Tata Motors cuts price of Tigor EV by ₹80,000

Tata Motors on Thursday said it has slashed its electric vehicles (EVs) prices by up to ₹80,000 following government's decision to bring down the GST on electric vehicles to 5 per cent. As of now, Tata Motors offers Tigor EV in the domestic market. The price reduction will be applicable across all the variants of Tigor EV, the company said.ln light of the recent announcement made by the government to slash the GST rates of all electric-powered vehicles from 12 per cent to 5 per cent, the price of Tata Motors EVs, will be reduced by up to Rs 80,000 starting August," said Shailesh Chandra, president for electric mobility business and corporate strategy, Tata Motors.Following the cut, the Tigor EV which was earlier priced between ₹12.35-12.71 lakh (ESP Mumbai) will now be available to customers at a starting price of ₹11.58-11.92 lakh, the company said. "However, these prices do not include the FAME (Faster Adoption and Manufacture of (Hybrid and) Electric Vehicles) subsidy & TCS," said Chandra. (Source: Businessline)

Exelixis inks pact with Dr Reddy's arm

US-based Exelixis Inc has entered into an exclusive collaboration with Aurigene Discovery Technologies, an arm of Dr Reddy's Laboratories Ltd. The agreement gives Exelixis, an oncology-focused biotechnology firm, the opportunity to in-license as many as six programmes from Aurigene, according to a statement by Exelixis Inc. Under the agreement terms, Exelixis will make an upfront payment of USD 10 million for exclusive options to license three pre-existing programmes from Aurigene, it added. In addition, Exelixis and Aurigene will initiate three Aurigene-led drug discovery programmes on mutually agreed upon targets, in exchange for additional option payments of \$2.5 million per programme, the statement said. Exelixis will also contribute research funding to Aurigene to facilitate discovery and preclinical development work on all six programmes, it added. As the programmes mature, Exelixis will have the opportunity to exercise an exclusive option for each programme up until the time of investigational new drug (IND) acceptance."If Exelixis decides to exercise an option, it will make an option exercise payment to Aurigene and assume responsibility for that programme's future clinical development and commercialisation including global manufacturing," it added. (Source: Businessline)



Morning Wealth

Nifty Top 5 Gainers	Close	Pts. Chg	% Chg
INFRATEL	251	5.2	2.1
WIPRO	270	5.1	1.9
MARUTI	5573	102.9	1.9
POWERGRID	214	3.2	1.5
EICHERMOT	16563	214.8	1.3

Nifty Top 5 Losers	Close	Pts. Chg	% Chg
VEDL	145	-8.7	-5.6
JSWSTEEL	225	-12.2	-5.1
SBIN	317	-15.1	-4.5
TATAMOTORS	130	-6.0	-4.5
HINDALCO	183	-7.8	-4.1

Int. Indices	Close	Pts. Chg	% Chg
S&P 500	2953.6	-26.8	-0.9
DOW	26583.4	-280.9	-1.1
NASDAQ	8111.1	-64.3	-0.8
FTSE	7584.9	-1.9	0.0
DAX	12253.2	64.1	0.5
CAC	5557.4	38.5	0.7
NIKKEI	20979.5	-561.5	-2.7
Hangseng	26913.0	-652.7	-2.4
Straits Times	3272.0	-19.7	-0.6

ADR	Close	Pts. Chg	% Chg
HDFC Bank	114.6	-0.4	-0.4
ICICI Bank	11.9	-0.3	-2.4
Infosys	11.3	-0.1	-0.5
Tata Motors	9.2	-0.5	-5.1
Wipro	4.2	0.1	1.4

Currencies	Close	Pts. Chg	% Chg
Dollar Index	98.4	-0.4	-0.4
USD/INR	69.0	-0.2	-0.3
EURO/INR	76.4	0.0	0.0
USD/YEN	107.0	-2.1	-1.9

Commodities	Close	Pts. Chg	% Chg
Gold Rs	34916.0	399.0	1.2
Silver Rs	40986.0	-241.0	-0.6
Crude (Brent) \$	62.1	1.6	2.6
Crude Oil (WTI) \$	55.1	1.1	2.1

Economy

Life insurance industry likely to see 14-15% growth: CARE

Betting big on the domestic life insurance industry, CARE Ratings said the sector is likely to grow at 14 per cent to 15 per cent per annum. In a research report released on Wednesday, it said the growth will come from a number of factors, including higher demand for retirement products such as pension and annuity, along with low availability of government-sponsored social security mechanisms and rising awareness of retirement planning and growing urbanisation. The sector will also witness growth due to factors such as the younger ones in the demographic chart opting for pure protection plans, push to increase insurance penetration in rural areas, product innovations, rise of multiple channels, and continued tax benefits. "CARE further expects regulatory changes and government initiatives to aid in the further penetration of insurance products in the medium term," it said, while highlighting challenges, including low income of individual agents, and low persistency ratio to continue to persist in the segment. "These challenges would need to be addressed to improve the depth and spread of the industry," it stressed. (Source: Businessline)

International News

India looks east amid US-China trade war

External Affairs Minister S Jaishankar, who is in Bangkok to attend the ASEAN Foreign Ministers meeting, will hold a number of bilaterals with his counterparts, although India is expected to take a cautious approach on many issues, including China's Belt and Road Initiative.New Delhi "does not want to alienate China," said Kanti Bajpai, director of the Centre on Asia and Globalisation at the National University of Singapore. "It will avoid commenting on Belt and Road and the South China Sea, it will be cautious on RCEP and it will probably avoid saying much on the Indo-Pacific.ASEAN has emerged as one of India's key trading partners in 2017-18, with a share of 10.58 per cent of overall trade. Bilateral trade has grown to \$81.33 billion in 2017-18 from \$56.24 billion in 2010-11.S Jaishankar will also hold talks with Chinese Foreign Minister Wang Yi during the meet.He will also meet US Secretary of State Michael Pompeo and British Foreign Secretary Dominic Raab in Bangkok. The meeting will be the first high-level interaction between the UK and India since Boris Johnson took the reins as Prime Minister. (Source: Businessline)

Major Bulk Deal (NSE)

Scrip Name	Qty	Type	Client Name	Trade Price
Strides Pharma	610700	Buy	R.B.A.FINANCE & INVT. CO	393

Major Bulk Deal (BSE)

Scrip Name	Qty	Туре	Client Name	Trade Price		
No Major Bulk deals						



Morning Wealth

EVENTS CALENDAR

Monday	Tuesday	Wednesday	Thursday	Friday
29-July-2019	30-July-2019	31-July-2019	1-Aug-2019	2-Aug-2019
RESULTS—	RESULTS-Granules India, Heromoto corp	RESULTS- Ashok Ley- land, Eicher Motors	RESULTS-	RESULTS- HDFC Ltd, SBI
Economic Indicators-	Economic Indicators-	Economic Indicators– Infrastructure Output (YoY) (Jun)	Economic Indicators– Nikkei Markit Manufac- turing PMI (Jul)	Economic Indicators-
US-	US-	US-	US-	US-
5-Aug-2019	6-Aug-2019	7-Aug-2019	8-Aug-2019	9-Aug-2019
RESULTS—	RESULTS-	RESULTS– Cipla Ltd, Mahindra & Mahindra	RESULTS-	RESULTS- Cadila Healthcare Ltd
Economic Indicators-	Economic Indicators-	Economic Indicators–	Economic Indicators-	Economic Indicators-
us-	us-	us-	us-	us-
12-Aug-2019	13-Aug-2019	14-Aug-2019	15-Aug-2019	16-Aug-2019
RESULTS—	RESULTS-	RESULTS-	RESULTS-	RESULTS-
Economic Indicators-	Economic Indicators-	Economic Indicators–	Economic Indicators–	Economic Indicators-
US-	US-	US-	US- ,	US-



Research Desk Tel: +91 22 61596406

Institutional Sales Desk Tel: +91 22 61596403/04/05

Disclaimer Appendix

Analyst (s) holding in the Stock: Nil

Analyst (s) Certification:

We analysts and the authors of this report, hereby certify that all of the views expressed in this research report accurately reflect our personal views about any and all of the subject issuer (s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation (s) or view (s) in this report. Analysts aren't registered as research analysts by FINRA and might not be an associated person of the BP Equities Pvt. Ltd. (Institutional Equities).

General Disclaimer

This report has been prepared by the research department of BP EQUITIES Pvt. Ltd, is for information purposes only. This report is not construed as an offer to sell or the solicitation of an offer to buy or sell any security in any jurisdiction where such an offer or solicitation would be illegal.

BP EQUITIES Pvt. Ltd have exercised due diligence in checking the correctness and authenticity of the information contained herein, so far as it relates to current and historical information, but do not guarantee its accuracy or completeness. The opinions expressed are our current opinions as of the date appearing in the material and may be subject to change from time to time. Prospective investors are cautioned that any forward looking statement are not predictions and are subject to change without prior notice.

Recipients of this material should rely on their own investigations and take their own professional advice. BP EQUITIES Pvt. Ltd or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. BP EQUITIES Pvt. Ltd. or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

BP EQUITIES Pvt. Ltd and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Opinions expressed are our current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by any person in any locality, state and country or other jurisdiction where such distribution, publication or use would be contrary to the law or regulation or would subject to BP EQUITIES Pvt. Ltd or any of its affiliates to any registration or licensing requirement within such jurisdiction.

Corporate Office:

4th floor,
Rustom Bldg,
29, Veer Nariman Road, Fort,
Mumbai-400001
Phone- +91 22 6159 6464
Fax-+91 22 6159 6160
Website- www.bpwealth.com

Registered Office:

24/26, 1st Floor, Cama Building, Dalal street, Fort, Mumbai-400001

BP Equities Pvt. Ltd.

CIN No: U67120MH1997PTC107392